898538-39-1

Usage

Uses

Used in Organic Synthesis:
1-bromo-5-(4-ethoxybenzyl)-2-methoxy-4-methylbenzene is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for multiple points of reactivity, facilitating the creation of a wide range of chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-bromo-5-(4-ethoxybenzyl)-2-methoxy-4-methylbenzene is used as a starting material for the development of new drugs. Its potential biological activity and medicinal properties are under investigation, with the aim of identifying novel therapeutic agents.
Used in Drug Discovery:
Due to its unique structure and properties, 1-bromo-5-(4-ethoxybenzyl)-2-methoxy-4-methylbenzene is utilized in drug discovery processes. Researchers explore its interactions with biological targets to uncover new avenues for treating diseases and improving healthcare outcomes.

Upstream product

• 1221506-25-7 (5-bromo-4-methoxy-2-methylphenyl)(4-ethoxyphenyl)methanone 
• 6245-57-4 4-methoxy-2-methylbenzoic acid 

Relevant academic research and scientific papers

5 - Bromo-benzoic acid with alkyl alkoxy -2 - -4 -

5 - Bromo-benzoic acid with alkyl alkoxy [to] -4 - -2 - production of high production efficiency. [Solution] According to one embodiment, in the presence of sulfuric acid, 4 - alkoxy-benzoic acid with alkyl bromide -2 - contact, 5 - bromo-benzoic acid alk

(1 S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

Derivatives of a novel scaffold, C-phenyl 1-thio-d-glucitol, were prepared and evaluated for sodium-dependent glucose cotransporter (SGLT) 2 and SGLT1 inhibition activities. Optimization of substituents on the aromatic rings afforded five compounds with potent and selective SGLT2 inhibition activities. The compounds were evaluated for in vitro human metabolic stability, human serum protein binding (SPB), and Caco-2 permeability. Of them, (1S)-1,5-anhydro-1-[5- (4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (3p) exhibited potent SGLT2 inhibition activity (IC50 = 2.26 nM), with 1650-fold selectivity over SGLT1. Compound 3p showed good metabolic stability toward cryo-preserved human hepatic clearance, lower SPB, and moderate Caco-2 permeability. Since 3p should have acceptable human pharmacokinetics (PK) properties, it could be a clinical candidate for treating type 2 diabetes. We observed that compound 3p exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in animals. Phase II clinical trials of 3p (TS-071) are currently ongoing.

1-THIO-D-GLUCITOL DERIVATIVES

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceu